According to background information in the article, routine newborn screening is required practice for newborn care throughout the United States. Traditionally, testing for various disorders required a separate test, but now with a measuring device called the tandem mass spectrometry, biochemical genetic screening of up to 20 disorders can be performed from only one blood sample from the newborn. To date 24 states have started this expanded newborn screening using tandem mass spectrometry. Four states have not yet implemented mandated programs and four states offer non-mandated expanded screening.
In this study, Susan E. Waisbren, Ph.D., from Children's Hospital, Boston, and colleagues compared newborn identification by expanded screening with clinical identification of biochemical genetic disorders. The researchers also assessed the impact on families of a false-positive screening result compared with a normal result. False-positive results are defined by the researchers as initial out-of-range screening results that do not signify a metabolic disorder on further evaluation of the child.
The sample included families of 50 affected children identified through expanded newborn screening and 33 affected children identified clinically. In addition, families of 94 children found to have false-positive newborn screening results and 81 children having normal newborn screening results were also enrolled. A total of 254 mothers and 153 fathers were interviewed.
"Within the first six months of life, 28 percent of children identified by newborn screening compared with 55 percent
Contact: Susan Craig
JAMA and Archives Journals